Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Jan;75(1):45-59.
doi: 10.1111/j.1365-2125.2012.04305.x.

Paediatric use of mycophenolate mofetil

Heather J Downing  1 , Munir Pirmohamed, Michael W Beresford, Rosalind L Smyth
Affiliations
Review

Paediatric use of mycophenolate mofetil

Heather J Downing et al. Br J Clin Pharmacol. 2013 Jan.

Abstract

A number of medications do not have a licence, or label, for use in the paediatric age group nor for the specific indication for which they are being used in children. Over recent years, mycophenolate mofetil has increasingly been used off-label (i.e. off-licence) in adults for a number of indications, including autoimmune conditions; progressively, this wider use has been extended to children. This review summarizes current use of mycophenolate mofetil (MMF) in children, looking at how MMF works, the pharmacokinetics, the clinical conditions for which it is used, the advantages it has when compared with other immunosuppressants and the unresolved issues remaining with use in children. The review aims to focus on off-label use in children so as to identify areas that require further research and investigation. The overall commercial value of MMF is limited because it has now come off patent in adults. Given the increasing knowledge of the pharmacodynamics, pharmacokinetics and pharmacogenomics demonstrating the clinical benefits of MMF, new, formal, investigator-led studies, including trials focusing on the use of MMF in children, would be of immense value.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Mycophenolic acid (MPA) inhibition of de novo synthesis of guanine nucleotide
Figure 2
Figure 2
Known metabolism of mycophenolate mofetil (MMF) in humans
See this image and copyright information in PMC

References

    1. Bentley R. Mycophenolic acid: a one hundred year odyssey from antibiotic to immunosuppressant [Review][201 refs] Chem Rev. 2000;100:3801–25. - PubMed
    1. Alsberg CL, Black F. Contribution to the study of maize deterioration; biochemical and toxicological investigations of Penicillium puberulum and Penicillium stoloniferum. U S Dept Agr, Bureau Plant Ind, Bull. 1913;270:1–47.
    1. Carter SB, Franklin TJ, Jones DF, Leonard BJ, Mills SD, Turner RW, Turner WB. Mycophenolic acid: an anti-cancer compound with unusual properties. Nature. 1969;223:848–50. - PubMed
    1. Allison AC. Mechanisms of action of mycophenolate mofetil. Lupus. 2005;14(Suppl. 1):s2–8. - PubMed
    1. Mele TS, Halloran PF. The use of mycophenolate mofetil in transplant recipients. [Review][130 refs] Immunopharmacology. 2000;47:215–45. - PubMed

Publication types